Hexima Ltd · ASX:HXL
Hexima — Shareholder Meeting (December 2021)
7 slides from Hexima's shareholder meeting presentation, Dec 2, 2021
Slide 1: 2021 Annual General Meeting – CEO's Presentation
HEXIMA LIMITED ASX ANNOUNCEMENT 02 November 2021 2021 ANNUAL GENERAL MEETING – CEO’S PRESENTATION For personal use only MELBOURNE, AUSTRALIA (2 December 2021): Hexima Limited (ASX:HXL) provides the attached CEO Presentation to be delivered at today’s Annual General Meeting commencing at 11.00am AEDT
Slide 2: Managing Director & Chief Executive Officer Presentation
For personal use only MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER PRESENTATION MR MICH A E L A LDRIDG E
Slide 3: Major Achievements FY2021
MA JO R AC H IE V E ME N TS F Y 2021 For personal use only CompliancePak Milestones & Achievements • Public Offering and listing on ASX o $3 million offering at A$0.20 per share • Phase IIb clinical trial o Initiation and completion of enrolment • Intellectual property protection • Scientific Adviso
Slide 4: Australian Phase IIb Clinical Trial
AUSTRALIAN PHASE IIB CLINICAL TRIAL H X P 1 2 4 -O NY-0 0 2 Enrolment For personal use only completed WEEK WEEK WEEK WEEK July 2021 13 24 36 40 • Multi-center, randomised, double blind, 12 WEEK DA ILY DO SING vehicle-controlled study • Primary endpoint safety and tolerability, 12 WEEK DA ILY DO SING
Slide 5: Strong patent position; clearly defined growth strategy
Strong patent position For personal use only A DDIT IO NA L P RO T E CT IO N VIA FO RMU LA T IO N P A T E NT S A ND MA RK E T E X CLU SIVIT Y FO R BIO LO G ICS Clearly defined growth strategy Granted patents Granted and 12-year US market (exp 2035) in major pending patents exclusivity on FDA • Devel
Slide 6: Looking Forward: A Pivotal Year in Growth and Development
LO O KIN G FO RWA R D A P IVOTA L Y EA R IN G ROWT H A ND DE VE LO P ME NT For personal use only Expected Milestones • Ongoing US focused Phase III preparations - Completed $11 million financing • Phase IIb clinical trial – data Q2 2022 • Corporate partnership(s) • Capital raising to fund phase III
Slide 7: Pezadeftide: a potential solution for a large and poorly served market
Pezadeftide: a potential solution for a large and poorly ser ved market For personal use only POORLY SERVED MARKET NEW AND UNIQUE SAFE CONVENIENT EFFECTIVE Affects 14% of the Novel molecule with No systemic effects Easy to apply Efficiently penetrates population unique mode of action No local rednes